However, it has been found that a strong expression of CD30 was mainly confined to tissue samples excided from patients in the tumor stage of the disease (25% of all tissue samples excided from a tumor stage MF showed a CD30 positivity > 7.8%), whereas a strong CD30 positivity was rarely found in the early MF stages (6.6% of all 45 tissue samples excided from a patch, plaque or parapsoriasis lesion). The gene discussed is TNFRSF8; the disease is parapsoriasis.